CN104994861B - 使用miRNA的癌症疗法 - Google Patents

使用miRNA的癌症疗法 Download PDF

Info

Publication number
CN104994861B
CN104994861B CN201380065503.0A CN201380065503A CN104994861B CN 104994861 B CN104994861 B CN 104994861B CN 201380065503 A CN201380065503 A CN 201380065503A CN 104994861 B CN104994861 B CN 104994861B
Authority
CN
China
Prior art keywords
mir
mirna
igf1r
melanoma
braf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380065503.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104994861A (zh
Inventor
P·J·雷德曼
K·M·吉雷斯
R·A·M·布朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Western Australia
Original Assignee
University of Western Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904570A external-priority patent/AU2012904570A0/en
Application filed by University of Western Australia filed Critical University of Western Australia
Publication of CN104994861A publication Critical patent/CN104994861A/zh
Application granted granted Critical
Publication of CN104994861B publication Critical patent/CN104994861B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380065503.0A 2012-10-18 2013-10-18 使用miRNA的癌症疗法 Expired - Fee Related CN104994861B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012904570A AU2012904570A0 (en) 2012-10-18 Cancer therapy using miRNAs
AU2012904570 2012-10-18
PCT/AU2013/001208 WO2014059484A1 (en) 2012-10-18 2013-10-18 CANCER THERAPY USING miRNAs

Publications (2)

Publication Number Publication Date
CN104994861A CN104994861A (zh) 2015-10-21
CN104994861B true CN104994861B (zh) 2019-10-11

Family

ID=50487345

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380065503.0A Expired - Fee Related CN104994861B (zh) 2012-10-18 2013-10-18 使用miRNA的癌症疗法

Country Status (5)

Country Link
US (1) US9795626B2 (enExample)
EP (1) EP2908830A4 (enExample)
CN (1) CN104994861B (enExample)
IN (1) IN2015DN04209A (enExample)
WO (1) WO2014059484A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201556B2 (en) * 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
ES2596711B1 (es) * 2015-07-09 2017-10-27 Fundacion Para La Investigacion Biomedica Del Hospital Universitario De La Paz Determinación de la metilación y niveles de un miARN en respuesta a un compuesto antitumoral basado en platino
CN106367419A (zh) * 2016-10-10 2017-02-01 徐州医科大学 具有神经保护作用的反义寡核苷酸、药物组合物及其应用
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3635396A4 (en) * 2017-06-06 2021-05-26 The Johns Hopkins University INDUCTION OF SYNTHETIC LETHALITY USING EPIGENETIC THERAPY
JP7354099B2 (ja) * 2017-10-03 2023-10-02 ジェネシーク ピーティーワイ リミテッド マイクロｒｎａ遺伝子発現を使用して黒色腫を診断し、病期分類し、モニタリングする方法
CN109536497A (zh) * 2018-11-28 2019-03-29 同济大学 日本血吸虫感染及其组分在人类肿瘤预防和治疗中的应用
US11750706B1 (en) * 2020-03-26 2023-09-05 Amazon Technologies, Inc. Data transmission time management
US12058196B1 (en) 2020-03-26 2024-08-06 Amazon Technologies, Inc. Data transfer timeout management

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063455A1 (en) * 2009-11-24 2011-06-03 The University Of Western Australia Modulation of epidermal growth factor receptor ligands

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2487260B1 (en) 2006-01-05 2015-07-08 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis and treatment of solid cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063455A1 (en) * 2009-11-24 2011-06-03 The University Of Western Australia Modulation of epidermal growth factor receptor ligands

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs;AH Yeh, et al.;《Oncogene》;20060522;第25卷;6574–6581 *
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation;Paul B. Chapman, et al.;《N Engl J Med.》;20110630;第364卷(第26期);2507–2516 *
MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor;X Zhao, et al.;《Oncogene》;20120521;第32卷;1363–1372 *

Also Published As

Publication number Publication date
US20150366895A1 (en) 2015-12-24
IN2015DN04209A (enExample) 2015-10-16
EP2908830A1 (en) 2015-08-26
WO2014059484A1 (en) 2014-04-24
CN104994861A (zh) 2015-10-21
EP2908830A4 (en) 2016-11-30
US9795626B2 (en) 2017-10-24

Similar Documents

Publication Publication Date Title
CN104994861B (zh) 使用miRNA的癌症疗法
AU2010324530B2 (en) Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors
Shan et al. MicroRNA-33a and let-7e inhibit human colorectal cancer progression by targeting ST8SIA1
KR20170098929A (ko) Hsp47 를 표적으로 하는 rnai 분자를 이용하는 악성 종양에 대한 치료적 조성물 및 방법
US20230090446A1 (en) Antisense oligonucleotide targeting linc00518 for treating melanoma
US10568901B2 (en) Micro-RNA for the treatment of malignant solid tumors and metastasis
KR20180039162A (ko) 간 질환 및 병태를 치료하기 위한 방법 및 조성물
US8247389B2 (en) Treatment of scleroderma
US20240287525A1 (en) Compositions and methods for treating cancer
JP2019508379A (ja) 悪性腫瘍に対する治療方法及び治療用組成物
WO2023183164A1 (en) Method of treating pancreatic cancer
CN114767864A (zh) Pak3抑制剂在治疗瑞芬太尼诱发的切口痛觉过敏中的应用
CN112739382A (zh) 使用了hsp47的抑制物质的化疗剂敏感性的增强
Singhania et al. Intraperitoneal delivery of liposomal siRNA for therapy of cervical cancer
WO2018088426A1 (ja) 抗癌剤及びその使用
WO2018157026A1 (en) Treatment of tumors with mirna targeting cdk4/cdk6
TW201717969A (zh) 用於治療與ｋｒａｓ突變相關之惡性腫瘤的方法與組成物
WO2014031807A1 (en) Sin3b complex inhibition and use thereof in the prevention of pro-oncogenic inflammation and cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20191011

Termination date: 20201018